Compare Stocks: CYAN, DARE, FNCH, and KPRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYAN Cyanotech	$0.45	$0.50	$0.23 ▼ $0.57	$3.33M	0.1	1,898 shs	500 shs
DARE Dare Bioscience	$0.75 -8.5%	$1.55	$0.74 ▼ $3.78	$12.55M	1.08	1.06 million shs	952,226 shs
FNCH Finch Therapeutics Group	$7.30	$7.30	$2.00 ▼ $16.10	$11.72M	1.18	5,025 shs	N/A
KPRX Kiora Pharmaceuticals	$2.59	$2.57	$1.76 ▼ $2.95	$11.46M	-0.38	16,806 shs	20,428 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYAN Cyanotech	0.00%	0.00%	-15.05%	-13.44%	+42.41%
DARE Dare Bioscience	+2.40%	+6.83%	-35.88%	-64.78%	-60.54%
FNCH Finch Therapeutics Group	0.00%	0.00%	0.00%	-2.01%	-39.17%
KPRX Kiora Pharmaceuticals	-5.82%	0.00%	+1.57%	-7.17%	-2.26%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYAN Cyanotech	$0.45	$0.50	$0.23 ▼ $0.57	$3.33M	0.1	1,898 shs	500 shs
DARE Dare Bioscience	$0.75 -8.5%	$1.55	$0.74 ▼ $3.78	$12.55M	1.08	1.06 million shs	952,226 shs
FNCH Finch Therapeutics Group	$7.30	$7.30	$2.00 ▼ $16.10	$11.72M	1.18	5,025 shs	N/A
KPRX Kiora Pharmaceuticals	$2.59	$2.57	$1.76 ▼ $2.95	$11.46M	-0.38	16,806 shs	20,428 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYAN Cyanotech	0.00%	0.00%	-15.05%	-13.44%	+42.41%
DARE Dare Bioscience	+2.40%	+6.83%	-35.88%	-64.78%	-60.54%
FNCH Finch Therapeutics Group	0.00%	0.00%	0.00%	-2.01%	-39.17%
KPRX Kiora Pharmaceuticals	-5.82%	0.00%	+1.57%	-7.17%	-2.26%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYAN Cyanotech	0.00	N/A	N/A	N/A
DARE Dare Bioscience	2.50	Moderate Buy	$10.00	1,232.27% Upside
FNCH Finch Therapeutics Group	0.00	N/A	N/A	N/A
KPRX Kiora Pharmaceuticals	2.00	Hold	$10.00	286.10% Upside

Current Analyst Ratings Breakdown

Latest CYAN, DARE, FNCH, and KPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/25/2026	DARE Dare Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/17/2026	DARE Dare Bioscience	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	DARE Dare Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	DARE Dare Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/14/2026	KPRX Kiora Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/26/2026	KPRX Kiora Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/11/2026	KPRX Kiora Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYAN Cyanotech	$26.59M	0.13	$0.08 per share	5.42	$1.08 per share	0.42
DARE Dare Bioscience	$1.03M	11.14	N/A	N/A	($0.04) per share	-18.77
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	$14.25 per share	N/A
KPRX Kiora Pharmaceuticals	$16.02M	0.71	N/A	N/A	$3.81 per share	0.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYAN Cyanotech	-$1.28M	-$0.25	N/A	N/A	N/A	-0.25%	-0.86%	-0.30%	N/A
DARE Dare Bioscience	-$13.40M	-$0.70	N/A	N/A	N/A	-803.80%	-748.30%	-38.75%	11/12/2026 (Estimated)
FNCH Finch Therapeutics Group	-$74.75M	-$8.82	N/A	N/A	N/A	N/A	-69.14%	-26.92%	N/A
KPRX Kiora Pharmaceuticals	-$10.84M	-$2.51	N/A	N/A	N/A	N/A	-63.38%	-44.33%	11/6/2026 (Estimated)

Latest CYAN, DARE, FNCH, and KPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	DARE Dare Bioscience	-$0.2967	-$0.20	+$0.0967	-$0.20	$0.00 million	$0.19 million
8/7/2026	Q2 2026	KPRX Kiora Pharmaceuticals	-$0.47	-$0.34	+$0.13	-$0.34	N/A	N/A
6/29/2026	Q3 2026	CYAN Cyanotech	N/A	N/A	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYAN Cyanotech	N/A	N/A	N/A	N/A	N/A
DARE Dare Bioscience	N/A	N/A	N/A	N/A	N/A
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A
KPRX Kiora Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYAN Cyanotech	0.13	1.06	0.42
DARE Dare Bioscience	N/A	0.99	0.99
FNCH Finch Therapeutics Group	N/A	3.87	3.87
KPRX Kiora Pharmaceuticals	N/A	8.97	8.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYAN Cyanotech	24.40%
DARE Dare Bioscience	6.70%
FNCH Finch Therapeutics Group	21.77%
KPRX Kiora Pharmaceuticals	76.97%

Insider Ownership

Company	Insider Ownership
CYAN Cyanotech	34.40%
DARE Dare Bioscience	4.10%
FNCH Finch Therapeutics Group	44.90%
KPRX Kiora Pharmaceuticals	0.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYAN Cyanotech	95	7.39 million	4.85 million	Not Optionable
DARE Dare Bioscience	30	15.29 million	14.66 million	Not Optionable
FNCH Finch Therapeutics Group	190	1.61 million	885,000	No Data
KPRX Kiora Pharmaceuticals	10	4.42 million	4.40 million	Not Optionable

CYAN, DARE, FNCH, and KPRX Headlines

Recent News About These Companies

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation

August 19, 2026 | newsfilecorp.comN

Analysts Have Conflicting Sentiments on These Healthcare Companies: Joint (JYNT) and Kiora Pharmaceuticals (KPRX)

August 9, 2026 | theglobeandmail.com

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 7, 2026 | newsfilecorp.comN

Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium

July 2, 2026 | newsfilecorp.comN

Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model

June 18, 2026 | newsfilecorp.comN

Kiora Pharmaceuticals Shareholders Approve Expanded Equity Incentive Plan

June 11, 2026 | tipranks.com

Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 8, 2026 | finanznachrichten.de

Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 8, 2026 | newsfilecorp.comN

Kiora’s phase 1 ABACUS study of KIO-301 in retinitis pigmentosa published in Nature Medicine; phase 2 trial underway

April 15, 2026 | eurekalert.orgE

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

April 14, 2026 | newsfilecorp.comN

Kiora's KIO-301 Study in Retinitis Published, Phase 2 On

April 14, 2026 | miragenews.comM

Why did KPRX stock surge 17% pre-market today?

April 7, 2026 | msn.com

Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors

April 7, 2026 | finance.yahoo.com

Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors

April 7, 2026 | finanznachrichten.de

Kiora Pharmaceuticals Announces Chief Development Officer Resignation

April 5, 2026 | theglobeandmail.com

Kiora Pharmaceuticals Announces Management Team Changes

April 2, 2026 | newsfilecorp.comN

Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials

March 25, 2026 | newsfilecorp.comN

Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference

February 19, 2026 | newsfilecorp.comN

Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board

January 27, 2026 | newsfilecorp.comN

Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds

December 1, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CYAN, DARE, FNCH, and KPRX Company Descriptions

Cyanotech OTCMKTS:CYAN

$0.45 0.00 (0.00%)

As of 09:38 AM Eastern

Cyanotech Corp. engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. Its products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant, which is used as a human dietary supplement and dietary ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye, joint, and immune health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company was founded by Gerald R. Cysewski in 1983 and is headquartered in Kailua-Kona, HI.

Dare Bioscience NASDAQ:DARE

$0.75 -0.07 (-8.54%)

As of 04:00 PM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Finch Therapeutics Group NASDAQ:FNCH

$7.30 0.00 (0.00%)

As of 08/25/2026

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Kiora Pharmaceuticals NASDAQ:KPRX

$2.59 0.00 (0.00%)

As of 04:00 PM Eastern

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CYAN, DARE, FNCH, and KPRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CYAN, DARE, FNCH, and KPRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CYAN, DARE, FNCH, and KPRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CYAN, DARE, FNCH, and KPRX Company Descriptions

Cyanotech OTCMKTS:CYAN

Dare Bioscience NASDAQ:DARE

Finch Therapeutics Group NASDAQ:FNCH

Kiora Pharmaceuticals NASDAQ:KPRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CYAN, DARE, FNCH, and KPRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CYAN, DARE, FNCH, and KPRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CYAN, DARE, FNCH, and KPRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CYAN, DARE, FNCH, and KPRX Company Descriptions

Cyanotech OTCMKTS:CYAN

Dare Bioscience NASDAQ:DARE

Finch Therapeutics Group NASDAQ:FNCH

Kiora Pharmaceuticals NASDAQ:KPRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools